lipegfilgrastim 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
granulocyte colony stimulating factor (G-CSF) type substances	4991	1117844-87-7

Description:

Molecule	Description
Synonyms: lipegfilgrastim lonquex XM22	A long acting glyco-pegylated recombinant form of human granulocyte colony-stimulating factor (G-CSF), with hematopoietic activity. Similar to G-CSF, lipegfilgrastim binds to and activates specific cell surface receptors, and stimulates neutrophil progenitor proliferation and differentiation. Therefore, this agent may prevent the duration and incidence of chemotherapy-induced neutropenia. Compared to filgrastim, lipegfilgrastim has a prolonged plasma half-life. Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

lipegfilgrastim
lonquex
XM22

A long acting glyco-pegylated recombinant form of human granulocyte colony-stimulating factor (G-CSF), with hematopoietic activity. Similar to G-CSF, lipegfilgrastim binds to and activates specific cell surface receptors, and stimulates neutrophil progenitor proliferation and differentiation. Therefore, this agent may prevent the duration and incidence of chemotherapy-induced neutropenia. Compared to filgrastim, lipegfilgrastim has a prolonged plasma half-life.

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
0.30	mg	P

ADMET properties:

None

Approvals:

Date	Agency	Company	Orphan
July 25, 2013	EMA	Sicor Biotech UAB

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Thrombocytopenia	93.62	46.55	50	1235	151107	63336630
Febrile neutropenia	90.07	46.55	45	1240	118404	63369333
Post-traumatic pain	60.51	46.55	10	1275	420	63487317
Neutropenia	58.59	46.55	39	1246	174966	63312771
Leukopenia	48.88	46.55	26	1259	77264	63410473

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Anal inflammation	101.80	55.41	21	1624	1279	34954007
SARS-CoV-2 test negative	94.80	55.41	19	1626	1001	34954285
Accident	91.84	55.41	25	1620	5022	34950264
Proctalgia	79.72	55.41	23	1622	5700	34949586
General physical health deterioration	75.55	55.41	56	1589	128213	34827073
Febrile neutropenia	72.32	55.41	56	1589	136793	34818493
Haemorrhoids	69.40	55.41	26	1619	14549	34940737
Testicular germ cell cancer metastatic	62.77	55.41	9	1636	57	34955229
Neutropenia	61.54	55.41	54	1591	156724	34798562

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Febrile neutropenia	132.45	45.06	91	2913	230908	79510476
Thrombocytopenia	130.16	45.06	95	2909	265164	79476220
Neutropenia	125.46	45.06	96	2908	287614	79453770
General physical health deterioration	107.27	45.06	86	2918	275152	79466232
Anal inflammation	98.46	45.06	20	2984	1410	79739974
SARS-CoV-2 test negative	87.47	45.06	18	2986	1353	79740031
Accident	79.11	45.06	24	2980	8807	79732577
Leukopenia	78.84	45.06	51	2953	116462	79624922
Proctalgia	67.93	45.06	22	2982	9979	79731405
Testicular germ cell cancer metastatic	64.90	45.06	9	2995	56	79741328
Haemorrhoids	54.34	45.06	25	2979	29103	79712281
Seminoma	54.31	45.06	9	2995	202	79741182
Post-traumatic pain	53.59	45.06	10	2994	451	79740933

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L03AA14	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSTIMULANTS IMMUNOSTIMULANTS Colony stimulating factors

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Chemotherapy-induced neutropenia	indication	425229001

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Granulocyte colony-stimulating factor receptor	Membrane receptor	Q99062	CSF3R_HUMAN	ACTIVATOR				DRUG LABEL	DRUG LABEL

External reference:

ID	Source
4AWF0N6QV3	UNII
D10242	KEGG_DRUG
C3640212	UMLSCUI
CHEMBL4594230	ChEMBL_ID
77910626	PUBCHEM_CID
DB13200	DRUGBANK_ID
9342	INN_ID
C455861	MESH_SUPPLEMENTAL_RECORD_UI
1440046	RXNORM
015533	NDDF
1268483008	SNOMEDCT_US
710282003	SNOMEDCT_US

Pharmaceutical products:

None